Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.73 |
| ▸ | RAB9A | P51151 | 10/20 | 0.73 |
| ▸ | CASP3 | P42574 | 1/20 | 0.65 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.65 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.65 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | MTOR | P42345 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1353484 | 0.80 | NPC1 (0.71) | NPC1RAB9ACASP3SENP7SENP6 | |
| SCHEMBL3770530 | 0.78 | NPC1 (0.71) | NPC1RAB9AKMT2AMEN1POLB | |
| SCHEMBL1353347 | 0.78 | KDM4E (0.74) | NPC1RAB9ACASP3SENP7SENP6 | |
| SCHEMBL3764363 | 0.77 | NPC1 (0.65) | NPC1RAB9ACASP3SENP7SENP6 | |
| SCHEMBL1353113 | 0.77 | RAB9A (0.64) | RAB9AKMT2AMEN1POLBALDH1A1 | |
| SCHEMBL1351165 | 0.77 | ALDH1A1 (0.64) | NPC1RAB9ACASP3SENP7SENP6 | |
| SCHEMBL1351504 | 0.76 | RAB9A (0.67) | NPC1RAB9AKMT2AMEN1RXFP1 | |
| SCHEMBL1353994 | 0.76 | RAB9A (0.65) | NPC1RAB9AMAP3K5KMT2AMEN1 | |
| SCHEMBL15595573 | 0.76 | NPC1 (0.77) | NPC1RAB9ACASP3SENP7SENP6 | |
| SCHEMBL1353420 | 0.75 | KDM4E (0.56) | NPC1RAB9AKMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063046-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-11-22 | — | — | US | disclosed |
| US-8063046-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-11-22 | — | — | US | disclosed |
| US-8063046-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-11-22 | — | — | US | disclosed |
| EP-1698618-B1 | BENZAMIDE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2011-05-18 | — | — | EP | disclosed |
| EP-1698618-B1 | BENZAMIDE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2011-05-18 | — | — | EP | disclosed |
| US-20100179326-A1 | BENZAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179326-A1 | BENZAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179326-A1 | BENZAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-15 | — | — | US | disclosed |
| US-7705053-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-04-27 | — | — | US | disclosed |
| US-7705053-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-04-27 | — | — | US | disclosed |
| US-7705053-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-04-27 | — | — | US | disclosed |
| US-20070123493-A1 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-31 | — | — | US | disclosed |
| US-20070123493-A1 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-31 | — | — | US | disclosed |
| US-20070123493-A1 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-31 | — | — | US | disclosed |
| EP-1698618-A1 | BENZAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123493-A1 | Benzamide derivative | BDKRB1, BDKRB2, NR1H2 | NPC1 540/4885RAB9A 2244/4885CASP3 1122/4885 |
| US-20100179326-A1 | BENZAMIDE DERIVATIVE | NR0B2, NR1H2, CNR2 | NPC1 955/4885RAB9A 2884/4885CASP3 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.